Bausch Health Reports Q1 2025 Financial Results

Bausch Health Companies ( (BHC) ) has released its Q1 earnings. Here is a breakdown of the information Bausch Health Companies presented to its investors.

Bausch Health Companies Inc. is a global diversified pharmaceutical company focused on developing, manufacturing, and marketing a wide range of products in areas such as gastroenterology, dermatology, and eye health, with a significant stake in Bausch + Lomb Corporation.

In the first quarter of 2025, Bausch Health reported consolidated revenues of $2.26 billion, marking a 5% increase from the previous year. Despite this revenue growth, the company recorded a GAAP net loss of $58 million, reflecting ongoing challenges in managing expenses and interest costs.

Key financial highlights include a steady adjusted EBITDA of $661 million, consistent with the previous year, and a successful $7.9 billion refinancing initiative aimed at improving the company’s capital structure. The Solta Medical segment showed notable growth with a 28% increase in revenues, driven by strong performance in South Korea and China.

Looking ahead, Bausch Health remains committed to evaluating strategic options to enhance shareholder value, including potential asset maximization and share buybacks. The company maintains its full-year revenue and adjusted EBITDA guidance, adjusting cash flow expectations to account for higher interest expenses.

Overall, Bausch Health is focused on sustaining its financial momentum and executing strategic priorities to ensure profitable growth and improved shareholder returns.